HHS
Harte Hanks, Inc.
There isn't enough reported data to score HHS yet.
VZ
Verizon Communications Inc.
VZ's fundamentals are mixed: it turned 28% of its revenue into free cash flow, but its operating margin fell 2 points to 21%. At 12x earnings, it's trading in line with its usual 11x. Analysts expect earnings growth.
HHS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
HHS's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
VZ Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Under pressure |
VZ's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
HHS PE Valuation
HHS has no meaningful PE right now: it lost money over the past year.
VZ PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.3x | $32.43 | -30% |
| Forward | 9x | $46.55 | — |
| Fair | 11x | $43.63 | -6.3% |
| Current | 12x | $46.55 | — |
| Expensive | 14x | $56.75 | +22% |
Historical ranges are pointers, not guarantees.
VZ's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 9.0x next year's earnings, in its cheap range.
HHS Forward outlook
There aren't enough analyst estimates for HHS to show an outlook.
VZ Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect VZ's earnings to grow and its profitability to improve, with its revenue holding steady.
HHS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.76 | -$0.37 |
| Q1 2026 | -$0.14 | +$4.04 |
| Q4 2025 | -$0.11 | +$4.04 |
| Q3 2025 | -$0.72 | +$3.38 |
| Q2 2025 | -$0.39 | +$3.65 |
| Q1 2025 | -$4.18 | -$4.06 |
| Q4 2024 | -$4.15 | -$3.94 |
| Q3 2024 | -$4.10 | -234% |
HHS is still losing money, but far less than before: $0.76 per share over the past year, against $4.27 at its worst in late 2019.
VZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.19 | +32% |
| Q3 2026 | $3.93 | -16% |
| Q2 2026 | $3.85 | -10% |
| Q1 2026 | $4.11 | -2.1% |
| Q4 2025 | $4.06 | -1.9% |
| Q3 2025 | $4.68 | +103% |
| Q2 2025 | $4.29 | +61% |
| Q1 2025 | $4.20 | +57% |
| Q4 2024 | $4.14 | +51% |
VZ has the edge over HHS on earnings quality, reporting a profit while its opponent remains loss making.
HHS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $38M | -1.7% |
| Q1 2026 | $37.3M | -10% |
| Q4 2025 | $39.9M | -15% |
| Q3 2025 | $39.5M | -17% |
| Q2 2025 | $38.6M | -14% |
| Q1 2025 | $41.6M | -8.6% |
| Q4 2024 | $47.1M | -4.8% |
| Q3 2024 | $47.6M | +1.1% |
HHS's revenue has slid since its 2022 peak: $38M last quarter, down 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -12% | -12 points |
| Q1 2026 | -2.1% | -2 points |
| Q4 2025 | -0.3% | +3 points |
| Q3 2025 | 1.3% | -2.7 points |
| Q2 2025 | 0.1% | -3 points |
| Q1 2025 | -0.1% | -0.9 points |
| Q4 2024 | -3.3% | +1.3 points |
| Q3 2024 | 4% | -2.2 points |
HHS's operating margin was −12% last quarter, down 12 points from the same quarter a year ago, near the bottom of its range since 2019.
VZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $34.3B | +1.5% |
| Q2 2026 | $34.3B | -0.7% |
| Q1 2026 | $34.4B | +2.9% |
| Q4 2025 | $36.4B | +2% |
| Q3 2025 | $33.8B | +1.5% |
| Q2 2025 | $34.5B | +5.2% |
| Q1 2025 | $33.5B | +1.5% |
| Q4 2024 | $35.7B | +1.6% |
VZ has the edge over HHS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 25% | +1.3 points |
| Q2 2026 | 21% | -2.7 points |
| Q1 2026 | 24% | +0.1 points |
| Q4 2025 | 14% | -7.1 points |
| Q3 2025 | 24% | +6.2 points |
| Q2 2025 | 24% | -0.2 points |
| Q1 2025 | 24% | +1 points |
| Q4 2024 | 21% | +19 points |
VZ has the edge over HHS on profitability, with a higher operating margin.
HHS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$3M |
| Q1 2026 | -$922K | +$1K |
| Q4 2025 | -$686K | -120% |
| Q3 2025 | $2.2M | +$7M |
| Q2 2025 | -$5.1M | -648% |
| Q1 2025 | -$923K | +$5.3M |
| Q4 2024 | $3.4M | +13% |
| Q3 2024 | -$4.9M | -474% |
HHS has burned cash in six of the last eight quarters: −$1M over the past year, against −$7M the year before.
VZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.5B | +2.2% |
| Q2 2026 | $10.4B | +16% |
| Q1 2026 | $8B | +2.6% |
| Q4 2025 | $9.1B | -13% |
| Q3 2025 | $11.3B | +14% |
| Q2 2025 | $9B | -5.4% |
| Q1 2025 | $7.8B | +9.9% |
| Q4 2024 | $10.4B | +20% |
VZ has the edge over HHS on cash generation, producing positive trailing cash flow while its opponent burns cash.
HHS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +15K shares |
| 1 year | +0.7% | +49K shares |
| 3 years | -1% | -74K shares |
| 5 years | +3.3% | +238K shares |
| Available history | +18% | +1.1M shares |
HHS has 7M diluted shares, up 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $491,000 |
VZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -10M shares |
| 1 year | -1.7% | -72M shares |
| 3 years | -1.3% | -55M shares |
| 5 years | +0.4% | +17M shares |
| Available history | +0.5% | +21M shares |
VZ has the edge over HHS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $500M |
| Q2 2026 | $1B |
| Q1 2026 | $2.5B |
HHS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.2x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.5x | Net Cash |
| Q3 2024 | -1.1x | Net Cash |
| Q2 2024 | -1.7x | Net Cash |
HHS has more cash than debt.
VZ Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.3x | Elevated |
| Q2 2026 | 3.4x | Elevated |
| Q1 2026 | 3.4x | Elevated |
| Q4 2025 | 2.9x | Moderate |
| Q3 2025 | 2.8x | Moderate |
| Q2 2025 | 3.0x | Moderate |
| Q1 2025 | 3.0x | Elevated |
| Q4 2024 | 3.0x | Elevated |
VZ's net debt is about 3.3 years of its operating earnings (EBITDA), up from 2.8 years a year ago.
HHS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 72.7 | Neutral |
HHS's weekly RSI is 57 (neutral) and its Stochastic is 73 (neutral).
VZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.9 | Neutral |
| Stochastic | 44.6 | Neutral |
VZ's weekly RSI is 51 (neutral) and its Stochastic is 45 (neutral).
HHS PE vs Communication Services Sector
| Metric | HHS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 16x | — |
HHS has no meaningful PE right now: it lost money over the past year.
VZ PE vs Communication Services Sector
| Metric | VZ | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 16x | 28% below |
| PE % | 58 | 26 | 32 pts above |
VZ is trading at 12x earnings, a 28% discount to the Communication Services sector's median of 16x.
HHS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.21 | 4.3% below |
| 20 week MA | $3.66 | 10% above |
| 50 week MA | $3.14 | 28% above |
| 100 week MA | $3.70 | 8.9% above |
| 200 week MA | $5.54 | 27% below |
HHS's trend is mixed: it's above three of its five weekly moving averages, and 27% below its 200-week average.
VZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $45.1 | 3.1% above |
| 20 week MA | $46.3 | 0.5% above |
| 50 week MA | $46.1 | 1.1% above |
| 100 week MA | $44.2 | 5.4% above |
| 200 week MA | $41.4 | 12% above |
VZ has the edge over HHS on trend strength, trading above more of its moving averages.
HHS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.46 | $2.55 | -26% |
| 2021 | $2.55 | $8.17 | +220% |
| 2022 | $8.17 | $11.5 | +41% |
| 2023 | $11.5 | $6.79 | -41% |
| 2024 | $6.79 | $5.38 | -21% |
| 2025 | $5.38 | $3.32 | -38% |
| 2026 YTD | $3.32 | $4.03 | +21% |
HHS has the edge over VZ on returns for 2026, with the stronger performance.
VZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $61.5 | $58.8 | -4.4% |
| 2021 | $58.8 | $52.7 | -10% |
| 2022 | $52.7 | $38.4 | -27% |
| 2023 | $38.4 | $37.7 | -1.8% |
| 2024 | $37.7 | $39.9 | +5.9% |
| 2025 | $39.9 | $40.5 | +1.4% |
| 2026 YTD | $40.5 | $46.6 | +15% |
VZ has finished lower in four of the last six years. It's up 15% so far in 2026.